Serum Levels of Selected Chemokines in Systemic Lupus Erythematosus Patients

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2012 Mar 31

PMID 22461186

Citations 9

Authors

Eugeniusz Hrycek

Andrzej Franek

Edward Blaszczak

Justyna Dworak

Antoni Hrycek

Affiliations

Soon will be listed here.

Abstract

Chemokines promote leukocyte traffic into the site of inflammation. Serum levels of monocyte chemotactic protein 1 (MCP-1), stromal cell-derived factor-1 (SDF-1), interferon-gamma-inducible protein 10 (IP-10), and interleukin-8 (IL-8) were evaluated in 48 treated women with systemic lupus erythematosus (SLE) and mild-to-moderate disease severity. The results were compared between the whole SLE group and the control (29 women). The relationships between chemokines, their concentrations, and peripheral blood leukocyte count and between the chemokines and individual leukocyte populations (polymorphonuclear leukocytes-PMNs, lymphocytes-Ls, monocytes-Ms, eosinophils) counts were determined. The relationships between the analyzed chemokines were also determined in the control. SLE subjects had significantly higher MCP-1, SDF-1, IP-10, and lower IL-8 concentrations compared to the control. Moderate, positive correlations between MCP-1/SDF-1, SDF-1/IP-10 and a negative correlation between MCP-1/IL8 were observed in the patient group. Moderate, negative correlations were found between SDF-1/total leukocyte count, SDF-1/absolute number of PMNs as well as between IP-10/total leukocyte count, IP-10/absolute PMNs, Ls, and Ms counts in peripheral blood of SLE group. We suggest that the obtained results and correlations observed between the examined parameters might be used to monitor SLE course and progression. However, further randomized clinical studies should be carried out on in untreated and treated patients with SLE.

Citing Articles

Tissue Kallikrein-1 Suppresses Type I Interferon Responses and Reduces Depressive-Like Behavior in the MRL/lpr Lupus-Prone Mouse Model.

Bhoj P, Nocito C, Togre N, Winfield M, Lubinsky C, Khan S Int J Mol Sci. 2024; 25(18).

PMID: 39337564 PMC: 11432477. DOI: 10.3390/ijms251810080.

Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews.

Guimaraes J, Furtado S, Lucas A, Mori B, Marques Barcellos J PLoS One. 2022; 17(10):e0275016.

PMID: 36215243 PMC: 9550089. DOI: 10.1371/journal.pone.0275016.

Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice.

Nocito C, Lubinsky C, Hand M, Khan S, Patel T, Seliga A Front Immunol. 2020; 11:573677.

PMID: 33042154 PMC: 7522287. DOI: 10.3389/fimmu.2020.573677.

Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.

Miyabe Y, Lian J, Miyabe C, Luster A Nat Rev Rheumatol. 2019; 15(12):731-746.

PMID: 31705045 DOI: 10.1038/s41584-019-0323-6.

Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.

Puapatanakul P, Chansritrakul S, Susantitaphong P, Ueaphongsukkit T, Eiam-Ong S, Praditpornsilpa K Int J Mol Sci. 2019; 20(19).

PMID: 31597273 PMC: 6801540. DOI: 10.3390/ijms20194954.

References

Matamoros M, Walker B, Van Dyke K, Van Dyke C . Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes. Pharmacology. 1983; 27(1):29-39. DOI: 10.1159/000137827. View

Narumi S, Takeuchi T, Kobayashi Y, Konishi K . Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000; 12(10):1561-5. DOI: 10.1006/cyto.2000.0757. View

Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I, Correia J . [CD4 lymphocytopenia in systemic lupus erythematosus]. Acta Reumatol Port. 2009; 34(2A):200-6. View

Hsieh S, Wu T, Tsai C, Li K, Lu M, Wu C . Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus. Rheumatology (Oxford). 2008; 47(2):150-7. DOI: 10.1093/rheumatology/kem320. View

Kotulova D, STEFANOVIC J . Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone. J Hyg Epidemiol Microbiol Immunol. 1983; 27(3):253-7. View

Lit L, Wong C, Tam L, Li E, Lam C . Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005; 65(2):209-15. PMC: 1798029. DOI: 10.1136/ard.2005.038315. View

Alzawawy A, Zohary M, Ablordiny M, Eldalie M . Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis. Int J Rheum Dis. 2010; 12(4):311-8. DOI: 10.1111/j.1756-185X.2009.01429.x. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Kong K, Tan A, Thong B, Lian T, Cheng Y, Teh C . Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol. 2009; 156(1):134-40. PMC: 2673751. DOI: 10.1111/j.1365-2249.2009.03880.x. View

10.

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

11.

Hrycek A, Pochopien-Kenig G, Scieszka J . Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity. 2007; 40(3):217-22. DOI: 10.1080/08916930701306817. View

12.

Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T . Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol. 1999; 26(3):568-73. View

13.

Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K . Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol. 2003; 30(7):1524-8. View

14.

Chong B, Mohan C . Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2009; 13(10):1147-53. DOI: 10.1517/14728220903196761. View

15.

Suzuki M, Hashizume M, Yoshida H, Mihara M . Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int. 2009; 30(3):309-15. DOI: 10.1007/s00296-009-0953-0. View

16.

Wang A, Guilpain P, Chong B, Chouzenoux S, Guillevin L, Du Y . Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum. 2010; 62(11):3436-46. PMC: 8972909. DOI: 10.1002/art.27685. View

17.

Brown K, Nackos E, Morthala S, Jensen L, Whitehead A, Von Feldt J . Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol. 2007; 34(4):740-6. View

18.

Szekanecz Z, Szucs G, Szanto S, Koch A . Chemokines in rheumatic diseases. Curr Drug Targets. 2006; 7(1):91-102. DOI: 10.2174/138945006775270231. View

19.

Ye D, Hu Y, Li X, Yang S, Hao J, Huang F . The correlation between monocyte chemoattractant protein-1 and the arthritis of systemic lupus erythematosus among Chinese. Arch Dermatol Res. 2004; 296(8):366-71. DOI: 10.1007/s00403-004-0531-y. View

20.

Link D . Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res. 2005; 32(1-3):169-78. DOI: 10.1385/IR:32:1-3:169. View